ClinicalTrials.gg
RecruitingNCT06371534Updated Feb 11, 2025

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

A Phase 1 interventional study of QL2109 and DARZALEX FASPRO® in Tumor, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2109 with DARZALEX FASPRO® in healthy male volunteers.

Participants will receive a single injection of QL2109/ DARZALEX FASPRO® Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the two groups.

Read the detailed description

This is a phase I, randomized, double-blind and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of single injections of QL2109 or DARZALEX FASPRO in healthy volunteers.

The secondary objective are to assess the clinical safety and immunogenicity similarity of single injections of QL2109 or DARZALEX FASPRO® in healthy volunteers.

Subjects would receive a single 1800mg#15ml# of QL2109 or DARZALEX FASPRO® injection.

02

Conditions studied

  • Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 228 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form and fully understand the test content,process and possible adverse reactions, and be able to complete the study according to the test plan requirements;
  • Age 18 \~ 50 (inclusive) years , male;
  • 65.0 kg≤ body weight ≤90.0 kg and 18.0 kg/m2≤ (BMI)

    ≤28.0 kg/m2;

  • Agree to use effective throughout the study period (including but not limited to: physical contraception, surgery, abstinence, etc.) until at least 6 months after the study dosing;
  • No history of disease or abnormal past medical history is not , and the study doctor's judgment has no impact on the trial.

Exclusion criteria

Exclusion Criteria:

  • Have been or are currently suffering from any clinically serious disease of the circulatory system, endocrine system, nervous system, digestive system,respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other disease that can interfere with the test results;
  • With acute, chronic, or latent infectious diseases within 1 month before administration;
  • With known immune system diseases ( diseases and immunodeficiency diseases), including but not limited to autoimmune hemolytic anemia;
  • Has experienced a recent single dermatomal herpes zoster eruption within 6 months before administration;
  • Has a history of multi-dermatomal herpes zoster or central nervous system (CNS) herpes zoster during the screening period or before;
  • Positive for indirect antiglobulin test (Indirect Coombs test);
  • Use of monoclonal antibody, cell therapy, etc. within 6 months before administration, or daratumumab or its analogues or drugs targeting CD38 before administration;
  • Use of any medication, including prescription drugs, over-the-counter (OTC) drugs, and Chinese herbal medicines, within 2 weeks before administration;
  • History of drug or food allergy, including allergy to any drug or drug used in the study;
  • Fear of needles or blood, or difficulty in venous blood collection (history of difficult blood collection or corresponding symptoms and signs, unable to tolerate venipuncture);
  • History of blood donation or total blood loss of 200 mL or more within 3 months before administration;
  • Participants in clinical trials of any other drug or device within 3 months (or 5 half-lives of the corresponding product if the half-life of the drug is long (5 half-lives > 3 months)) before administration;
  • Major surgery within 3 months before signing the ICF;
  • Positive for virus antibodies, virus (HCV) antibodies, (HIV), or treponema pallidum antibodies (Anti-TP);
  • History of drug abuse or substance abuse, or positive in urine drug screening;
  • Patients who have been vaccinated with attenuated or (such as Bacille Calmette-Guérin, BCG) or viral vector vaccine within 12 months before the first dose, or who plan to be vaccinated with such vaccines within 12 months after administration;
  • Patients who have been vaccinated with vaccines other than the above attenuated or live viral vaccines and viral vector vaccines within 1 month before the first dose, such as inactivated vaccines and recombinant subunit vaccines;
  • Subjects with any other conditions that, in the judgment of the investigator, are ineligible for participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    QL2109

    QL2109, subcutaneous injection 3-5 min D1 (Day 1, single dose)

    Drug: QL2109

  • Active comparator
    DARZALEX FASPRO®

    DARZALEX FASPRO®, subcutaneous injection 3-5 min D1 (Day 1, single dose)

    Drug: DARZALEX FASPRO®

Interventions

  • DrugQL2109

    subcutaneous injection 3-5 min D1 (Day 1, single dose)

  • subcutaneous injection 3-5 min D1 (Day 1, single dose)

06

What researchers measure

Primary outcomes

  1. AUC0-∞

    To evaluate pharmacokinetic similarity between QL2109 and DARZALEX FASPRO ® after a single subcutaneous injection in healthy volunteers

    Time frame: 112 day

  2. Cmax

    To evaluate pharmacokinetic similarity between QL2109 and DARZALEX FASPRO® after a single subcutaneous injection in healthy volunteers

    Time frame: 112 day

07

Study locations

1 of 2 sites recruiting
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310006, China
    Recruiting
    • qingwei zhao, Professor · Contactqwzhao@zju.edu.cn · +086-13588066886
    • qingwei zhao, Professor · Principal investigator
    • xingjiang hu, Professor · Principal investigator
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310006, China
    Not yet recruiting
    • qingwei ZHAO, Professor · Contactqwzhao@zju.edu.cn
    • xingjiang HU, Professor · Contacthxj319@163.com
    • qingwei ZHAO, Professor · Principal investigator
    • xingjiang HU, Professor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2025, 12 months after the start.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2024
First posted
Apr 17, 2024
StartActual
Apr 12, 2024
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06371534
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Apr 12, 2024
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Feb 11, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL2109

Start the discussion